Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_assertion type Assertion NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_head.
- NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_assertion description "[Depending on the cell line and the vector construct used, lymphokine gene-modified human RC cell lines released 4 to 29 units/10(6) cells of IL-2, or up to 10 units/10(6) cells of IFN-gamma within 48 h. Fluorescence-activated cell sorter analysis of SK-RC-29 cells releasing IFN-gamma showed increased expression of major histocompatibility complex class I antigen, beta 2-microglobulin, and ICAM-1, as well as induction of major histocompatibility complex class II antigen expression [human leukocyte antigen(HLA)-DR, -DP], but no changes in these cell surface markers were observed with SK-RC-29 cells releasing IL-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_provenance.
- NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_assertion evidence source_evidence_literature NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_provenance.
- NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_assertion SIO_000772 1423266 NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_provenance.
- NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_assertion wasDerivedFrom befree-2016 NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_provenance.
- NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_assertion wasGeneratedBy ECO_0000203 NP413320.RAz4voc-pSArJ05OP3gTvVzuoNIqjZh8-wiB11_QFOV9A130_provenance.